Tags

Type your tag names separated by a space and hit enter

Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma.
Br J Clin Pharmacol. 2002 Dec; 54(6):622-6.BJ

Abstract

AIMS

Angiotensin II is a putative mediator in bronchial asthma. There have been very few studies investigating the involvement of angiotensin II receptors in bronchial hyper-responsiveness in asthmatic patients. We examined the effect of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in patients with asthma.

METHODS

Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1), was measured on three occasions 2 weeks apart in 11 stable asthmatic patients. Candesartan cilexetil (8 mg once a day) or a placebo was orally administered for 1 week before the methacholine provocation test in a double-blind, randomized, crossover manner.

RESULTS

Although there were no significant differences between treatment periods in FEV1 values at baseline, the geometric mean (95% CI) PC20-FEV1 values increased significantly (P = 0.041) from 0.691 (0.379, 1.259) mg ml-1 with placebo to 0.837 (0.506, 1.384) mg ml-1 with candesartan. Candesartan decreased the mean (95% CI) arterial blood pressure (placebo: 95.6 (89.0, 102.2) mmHg, candesartan: 86.4 (79.8, 93.1) mmHg, P = 0.015). There was no correlation between the change in blood pressure and the change in PC20-FEV1.

CONCLUSIONS

We conclude that AT1 receptors are involved in bronchial hyper-responsiveness in asthmatic patients.

Authors+Show Affiliations

The Third Department of Internal Medicine, Kanazawa University School of Medicine, 13-1 Takara-machi, Kanazawa 920-8641, Japan. myous@nifty.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12492610

Citation

Myou, Shigeharu, et al. "Effect of Candesartan, a Type 1 Angiotensin II Receptor Antagonist, On Bronchial Hyper-responsiveness to Methacholine in Patients With Bronchial Asthma." British Journal of Clinical Pharmacology, vol. 54, no. 6, 2002, pp. 622-6.
Myou S, Fujimura M, Kamio Y, et al. Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma. Br J Clin Pharmacol. 2002;54(6):622-6.
Myou, S., Fujimura, M., Kamio, Y., Kita, T., Watanabe, K., Ishiura, Y., Hashimoto, T., & Nakao, S. (2002). Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma. British Journal of Clinical Pharmacology, 54(6), 622-6.
Myou S, et al. Effect of Candesartan, a Type 1 Angiotensin II Receptor Antagonist, On Bronchial Hyper-responsiveness to Methacholine in Patients With Bronchial Asthma. Br J Clin Pharmacol. 2002;54(6):622-6. PubMed PMID: 12492610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma. AU - Myou,Shigeharu, AU - Fujimura,Masaki, AU - Kamio,Yumie, AU - Kita,Toshiyuki, AU - Watanabe,Kazuyoshi, AU - Ishiura,Yoshihisa, AU - Hashimoto,Takuma, AU - Nakao,Shinji, PY - 2002/12/21/pubmed PY - 2003/3/7/medline PY - 2002/12/21/entrez SP - 622 EP - 6 JF - British journal of clinical pharmacology JO - Br J Clin Pharmacol VL - 54 IS - 6 N2 - AIMS: Angiotensin II is a putative mediator in bronchial asthma. There have been very few studies investigating the involvement of angiotensin II receptors in bronchial hyper-responsiveness in asthmatic patients. We examined the effect of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on bronchial responsiveness to inhaled methacholine in patients with asthma. METHODS: Bronchial responsiveness to methacholine, assessed as the concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1), was measured on three occasions 2 weeks apart in 11 stable asthmatic patients. Candesartan cilexetil (8 mg once a day) or a placebo was orally administered for 1 week before the methacholine provocation test in a double-blind, randomized, crossover manner. RESULTS: Although there were no significant differences between treatment periods in FEV1 values at baseline, the geometric mean (95% CI) PC20-FEV1 values increased significantly (P = 0.041) from 0.691 (0.379, 1.259) mg ml-1 with placebo to 0.837 (0.506, 1.384) mg ml-1 with candesartan. Candesartan decreased the mean (95% CI) arterial blood pressure (placebo: 95.6 (89.0, 102.2) mmHg, candesartan: 86.4 (79.8, 93.1) mmHg, P = 0.015). There was no correlation between the change in blood pressure and the change in PC20-FEV1. CONCLUSIONS: We conclude that AT1 receptors are involved in bronchial hyper-responsiveness in asthmatic patients. SN - 0306-5251 UR - https://www.unboundmedicine.com/medline/citation/12492610/Effect_of_candesartan_a_type_1_angiotensin_II_receptor_antagonist_on_bronchial_hyper_responsiveness_to_methacholine_in_patients_with_bronchial_asthma_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0306-5251&date=2002&volume=54&issue=6&spage=622 DB - PRIME DP - Unbound Medicine ER -